Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'research area stem cell stem gsk 3'

Search results for: 'research area stem cell stem gsk 3'

Items 21-30 of 110

Page
per page
  1. MNS
    A8661 MNS
    Summary: Inhibitor of Src/Syk tyrosine kinases
  2. GZD824
    B1402 GZD824
    Target: Bcr-Abl
    Summary: Bcr-Abl inhibitor,novel orally bioavailable
      ≥36.25 mg/mL
  3. Cabozantinib malate (XL184)
    B1401 Cabozantinib malate (XL184)
    Summary: MET andVEGF receptor2 inhibitor
      ≥31.8 mg/mL
  4. BMX-IN-1
    A3260 BMX-IN-1
    Summary: BMX (also termed ETK) kinase inhibitor
      insoluble in H2O; insoluble in EtOH; ≥5.25 mg/mL
  5. Dasatinib hydrochloride
    A3351 Dasatinib hydrochloride
    Summary: Multi-BCR/Abl and Src kinase inhibitor, oral active
      insoluble in EtOH; insoluble in H2O; ≥8.41 mg/mL
  6. Regorafenib hydrochloride
    A3750 Regorafenib hydrochloride
    Target: Raf|VEGFR|PDGFR|c-Kit|c-RET
    Summary: Tyrosine kinase inhibitor
      ≥25.95 mg/mL
  7. SU 5402
    A3843 SU 5402
    Target: VEGFR|PDGFR|FGFR
    Summary: VEGFR2/FGFR/PDGFR/EGFR inhibitor
      insoluble in EtOH; insoluble in H2O; ≥14.8 mg/mL
  8. ML347
    B3688 ML347
    Target: BMP and Other Activin Receptors
    Summary: BMP receptor inhibitor,potent and selective
      insoluble in H2O; insoluble in EtOH; ≥5.87 mg/mL
  9. Amuvatinib (MP-470, HPK 56)
    A4237 Amuvatinib (MP-470, HPK 56)
    Summary: Tyrosine kinase inhibitor
      ≥22.4 mg/mL
  10. NT157
    B7808 NT157
     1 Citation
    Summary: IRS-1/2 inhibitor, inhibits IGF-1R and STAT3 signaling pathway

Items 21-30 of 110

Page
per page
Shop By
Now Shopping by
  1. Category Tyrosine Kinase Remove This Item
Clear All
Shopping Options
Category
  1. Bcr-Abl 4item
  2. Axl 2item
  3. ALK 7item
  4. BMX Kinase 1 item
  5. Broad Spectrum Protein Kinase Inhibitor 1 item
  6. c-FMS 1 item
  7. c-Kit 5item
  8. c-MET 5item
  9. c-RET 7item
  10. CSF-1R 1 item
  11. EGFR 18item
  12. FAK 1 item
  13. FGFR 7item
  14. FLT3 12item
  15. HER2 4item
  16. IGF1R 2item
  17. Insulin Receptor 2item
  18. IRAK 1 item
  19. Lck 1 item
  20. LRRK2 4item
  21. PDGFR 7item
  22. PTKs/RTKs 1 item
  23. Pyk2 1 item
  24. ROR 2item
  25. Spleen Tyrosine Kinase (Syk) 4item
  26. Src 5item
  27. Tie-2 2item
  28. Trk 5item
  29. VEGFR 26item
Specificity
  1. Selective 39item
Reversibility
  1. Reversible 2item
  2. Irreversible 2item
Target
  1. Cyclin-Dependent Kinases 1 item
  2. Raf 3item
  3. Aurora Kinases 2item
  4. CSF-1R 1 item
  5. MER 1 item
  6. FLT3 6item
  7. VEGFR 20item
  8. PDGFR 15item
  9. c-Kit 8item
  10. RET 2item
  11. IRAK 1 item
  12. Bcr-Abl 4item
  13. FGFR 6item
  14. MET 2item
  15. Src 3item
  16. Trk Receptors 2item
  17. EGFR 10item
  18. BMP and Other Activin Receptors 1 item
  19. Syk 1 item
  20. ErbB 2item
  21. c-MET 2item
  22. PKC 1 item
  23. Ca2 /calmodulin-dependent protein kinases (CaMKs) 1 item
  24. Lyn 1 item
  25. HER2 1 item
  26. LRRK2 3item
  27. ALK 2item
  28. Insulin-like growth factors (IGFs) 1 item
  29. CSF1R 1 item
  30. Tie-2 1 item
  31. Ron 1 item
  32. c-Fyn 1 item
  33. Insulin Receptors 1 item
  34. IRG-1R 1 item
  35. c-RET 2item
  36. c-Fms tyrosine kinase 1 item
  37. insulin 1 item
  38. DCLK2 1 item
Reported Experiments
  1. Animal Experiments 51item
  2. Cell Experiments 36item
Related Disease
  1. Acute Myelogenous Leukemia 1 item
  2. Acute Myeloid Leukemia 1 item
  3. Advanced Renal Cell Carcinoma 1 item
  4. Autoimmune Diseases 1 item
  5. Bladder Cancer 3item
  6. Breast Cancer 13item
  7. Cancer 39item
  8. Colon Cancer 2item
  9. Colorectal Cancer 8item
  10. Glioblastoma 4item
  11. Liver Cancer 1 item
  12. Lung Cancer 4item
  13. Melanoma 1 item
  14. Multiple Myeloma 3item
  15. Neuroblastoma 1 item
  16. Non-small Cell Lung Cancer 2item
  17. Ovarian Cancer 4item
  18. Pancreatic Cancer 5item
  19. Prostate Cancer 4item
  20. Pulmonary Arterial Hypertension 1 item
  21. Renal Cell Carcinoma 2item
  22. Thyroid Cancer 2item